<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1320">
  <stage>Registered</stage>
  <submitdate>9/10/2006</submitdate>
  <approvaldate>9/10/2006</approvaldate>
  <nctid>NCT00386360</nctid>
  <trial_identification>
    <studytitle>Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method</studytitle>
    <scientifictitle>A Non-Invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D-Peripheral Quantitative Computed Tomography (3D-pQCT)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2005040</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteopenia</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo comparator
Treatment: drugs - risedronate

Placebo Comparator: Placebo - Placebo dose

Experimental: Risedronate - 35 mg risedronate, orally, once weekly


Treatment: drugs: Placebo comparator
oral weekly for one year

Treatment: drugs: risedronate
35 mg risedronate, once a week for one year

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Trabecular Bone Volume to Tissue Volume at Distal Radius, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Average Bone Density at Distal Radius, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compact Bone Density at Distal Radius, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trabecular Bone Density at Distal Radius, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Average Bone Density at Distal Tibia, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compact Bone Density at Distal Tibia, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trabecular Bone Density at Distal Tibia, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lumbar Spine BMD, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Proximal Femur BMD (Bone Mineral Density), Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Femoral Neck BMD, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Greater Trochanter BMD, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Type I Collagen C-Telopeptides, Serum, Percent Change From Baseline to Month 12 - ELISA / enzyme-linked immunosorbent assay method by central lab</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Procollagen Type 1 N-Propeptide, Percent Change From Baseline to Month 12 - Electrochemiluminescence assay method by central lab</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Height, Percent Change From Baseline to Month 12</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  cessation of menstruation (surgical or natural) between 6 and 36 months prior to study
             enrollment;

          -  osteopenic

          -  must have at least 1 evaluable radius and tibia, without history of fracture
             (traumatic or atraumatic)

          -  BMI (body mass index) between 18 and 28 kg/m2 inclusive;</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  history of any generalized bone disease, including hyperparathyroidism, Paget's
             disease of bone, renal osteodystrophy, or any other acquired or congenital bone
             disease; or any known condition that would interfere with the assessment of DXA
             (dual-energy X-ray absorptiometry) at either the lumbar spine (3 non-evaluable lumbar
             vertebrae at lumbar spine L1 - L4) or the femoral neck.

          -  clinical or radiological evidence of osteoporosis, such as atraumatic vertebral
             compression fracture (* 20% reduction in anterior-to-posterior or middle-to-posterior
             height ratio; or 20% reduction of the anterior, middle, and/or posterior height as
             compared with the adjacent vertebrae) documented by spinal X ray or a history of
             osteoporosis-related atraumatic fracture of the hip or of the wrist;

          -  glucocorticoid-induced osteopenia;

          -  previous bisphosphonate therapy;</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>161</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Research Facility - Heidelberg</hospital>
    <postcode>3081 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Etienne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Warner Chilcott</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the protocol is to evaluate the sensitivity of 3D-pQCT (3D-Peripheral
      Quantitative Computed Tomography) technology to detect minute changes in bone
      microarchitecture.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00386360</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gioacchino D'Alo, MD</name>
      <address>P&amp;G Pharmaceuticals, Clinical Development Europe</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>